Phase II year
2010
(last award dollars: 2011)
The goal of this Phase II SBIR proposal is to expand upon the research and development efforts, begun in Phase I, with new enhancements and product offerings, while also taking the initial steps to position the Company for a multi-center clinical trial, planned for Phase III. Phase I efforts have led to the development and commercialization of the Company's first product, IB NeuroTM 1.0, which received FDA 510K clearance for indications of brain tumors and stroke. This product uses perfusion analysis algorithms, which were proven to be the most robust in a multi-year comparison study performed in patients with brain tumors. A key element of the product is the leakage correction algorithms, critical for the accurate evaluation of brain tumors. Currently no other perfusion analysis software product with FDA clearance incorporates leakage correction algorithms. Therefore, the IB Neuro 1.0 product makes available, for the first time, advanced and proven algorithms for the analysis of MRI perfusion data in a robust and easy-to-use fashion. Given this early success, the specific objectives of this Phase II proposal are to extend the functionality of IB NeuroTM in three important ways. First, additional tools will be added to enable comparison of imaging data across studies. This capability is especially important for the most efficient and accurate evaluation of both standard treatments (such as chemotherapy and radiation therapy) and for the newly available and promising biologic agents that target a tumor's new blood vessel growth (angiogenesis). Second, the Company's patented dual-echo perfusion technology will be developed as part of IB Neuro 1.1. With this proprietary technology DSC (dynamic susceptibility contrast) and DCE (dynamic contrast enhanced) perfusion data can be simultaneously collected while using only a single dose of contrast agent. IB Neuro 1.1. will incorporate the tools to generate relevant perfusion parameters including CBV (cerebral blood volume), CBF (cerebral blood flow) as well as Ktrans, a marker of vascular permeability. A third objective is to incorporate the functionality necessary to more specifically support the evaluation of perfusion data for the evaluation of stroke. Each of these product development objectives will be accomplished in the context of receiving frequent feedback from the Company's luminary sites. This will position the Company for the multi-center trials planned for Phase III. Overall the technological niche of IB, which is to develop advanced imaging analysis tools that plug into existing vendors'systems, will enable advanced imaging options to become more widely available to clinics and therefore patients in a cost-effective manner. The result will be to provide the best and most state-of-the- art patient care on a more widespread basis. This has the potential to shift current clinical practice paradigms with regard to how treatments are planned and monitored, as none of these proven advanced technologies have been previously available on a wide-spread basis. , ,
Public Health Relevance: The goal of this Phase II SBIR proposal is to enable the Company, Imaging Biometrics LLC, to continue its development and distribution of innovative and proven perfusion and diffusion analysis software for the evaluation of brain tumors and stroke. While stand-alone options are available, the primary approach is to develop the software to plug into existing vendors'systems. With this approach the best and most up-to-date image analysis software can be made available on a widespread and cost-effective basis, which has the potential to shift current clinical practice paradigms for treatment planning and monitoring.
Thesaurus Terms: Address;Algorithms;Angiogenesis Antagonists;Angiogenesis Blockers;Angiogenesis Inhibitors;Angiogenetic Antagonists;Angiogenic Antagonists;Angiostatic Agents;Anti-Angiogenetic Agents;Anti-Angiogenic Agents;Anti-Angiogenic Drugs;Antiangiogenesis Agents;Antiangiogenic Agents;Apoplexy;Area;Arts;Biometrics;Biometry;Biometry And Biostatistics;Biostatistics;Blood Vessels;Blood Volume;Brain;Brain Neoplasia;Brain Neoplasms;Brain Tumors;Cancer Radiotherapy;Cerebral Stroke;Cerebrovascular Apoplexy;Cerebrovascular Circulation;Cerebrovascular Stroke;Cerebrovascular Accident;Cerebrum;Clinic;Computer Programs;Computer Software;Contrast Agent;Contrast Drugs;Contrast Media;Data;Development;Development And Research;Diffusion;Disease;Disorder;Dose;E-Mail;Electronic Mail;Elements;Email;Encephalon;Encephalons;Evaluation;Extravasation;Feedback;Future;Generalized Growth;Generations;Goals;Growth;Health Care Industry;Healthcare Industry;Human Resources;Image;Image Analyses;Image Analysis;Imaging Technology;Industry, Healthcare;Infarction;Inhibitors, Angiogenetic;Inhibitors, Angiogenic;Ischemia;Leakage;Legal Patent;Manpower;Maps;Methods;Monitor;Multi-Institutional Clinical Trial;Multi-Center Clinical Study;Multi-Center Clinical Trial;Multi-Site Clinical Study;Multi-Site Clinical Trial;Neovascularization Inhibitors;Nervous System, Brain;Patents;Patient Care;Patient Care Delivery;Patients;Perfusion;Phase;Physicians;Plug-In;Position;Positioning Attribute;Predisposition;R & D;R&D;R01 Mechanism;R01 Program;Roc Analysis;Rpg;Radiation Therapy;Radiopaque Media;Radiotherapeutics;Radiotherapy;Reporting;Research Grants;Research Project Grants;Research Projects;Research Projects, R-Series;Risk;Sbir;Sbirs (R43/44);Site;Site Visit;Small Business Innovation Research;Small Business Innovation Research Grant;Software;Solid Neoplasm;Solid Tumor;Spillage;Stroke;Susceptibility;System;System, Loinc Axis 4;Technology;Testing;Time;Tissue Growth;Translating;Translatings;Validation;Vascular Accident, Brain;Vascular Permeabilities;Vendor;Weight;Angiogenesis;Antiangiogenic;Base;Brain Attack;Cerebral Blood Flow;Cerebral Circulation;Cerebral Vascular Accident;Cerebrocirculation;Chemotherapy;Clinical Practice;Commercialization;Computer Program/Software;Computerized Data Processing;Conference;Cost;Data Processing;Develop Software;Developing Computer Software;Disease/Disorder;Image Evaluation;Imaging;Imaging Modality;Indexing;Infarct;Innovate;Innovation;Innovative;Interest;Irradiation;Language Translation;Meetings;Multi Center Clinical Study;Multi Center Clinical Trial;Multi Site Clinical Study;Multi Site Clinical Trial;Neuro-Oncology;Novel;Ontogeny;Patient Population;Personnel;Product Development;Public Health Relevance;Research And Development;Signal Processing;Software Development;Standard Care;Statistics/Biometry;Stroke;Success;Symposium;Tool;Treatment Planning;Trend;Tumor;Tumors In The Brain;Vascular